iTeos Therapeutics, Inc. – NASDAQ:ITOS
iTeos Therapeutics stock price today
$10.13
+2.81
+38.39%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
iTeos Therapeutics stock price monthly change
-54.70%
month
iTeos Therapeutics stock price quarterly change
-54.70%
quarter
iTeos Therapeutics stock price yearly change
-31.97%
year
iTeos Therapeutics key metrics
Market Cap | 264.87M |
Enterprise value | 188.44M |
P/E | 5.05 |
EV/Sales | 0.88 |
EV/EBITDA | 1.46 |
Price/Sales | 2.18 |
Price/Book | 0.70 |
PEG ratio | -0.05 |
EPS | -3.78 |
Revenue | N/A |
EBITDA | -167.16M |
Income | -135.30M |
Revenue Q/Q | -100% |
Revenue Y/Y | -108.85% |
Profit margin | 35.19% |
Oper. margin | 58.95% |
Gross margin | 0% |
EBIT margin | 58.95% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeiTeos Therapeutics stock price history
iTeos Therapeutics stock forecast
iTeos Therapeutics financial statements
| Jun 2023 | 0 | -34.3M | |
|---|---|---|---|
| Sep 2023 | 0 | -32.24M | |
| Dec 2023 | -11.30M | -30.55M | 270.29% |
| Mar 2024 | 0 | -38.21M |
| Sep 2025 | 0 | -53.75M | |
|---|---|---|---|
| Oct 2025 | 0 | -51.34M | |
| Dec 2025 | 0 | -55.03M | |
| Mar 2026 | 0 | -65.43M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 703746000 | 80.22M | 11.4% |
|---|---|---|---|
| Sep 2023 | 677644000 | 79.38M | 11.71% |
| Dec 2023 | 667588000 | 92.36M | 13.83% |
| Mar 2024 | 629769000 | 88.56M | 14.06% |
| Jun 2023 | -29.54M | 20.10M | 218K |
|---|---|---|---|
| Sep 2023 | -33.89M | 22.69M | 10K |
| Dec 2023 | -13.76M | 61.55M | 307K |
| Mar 2024 | -32.4M | -69.6M | 22K |
iTeos Therapeutics alternative data
| Aug 2023 | 125 |
|---|---|
| Sep 2023 | 125 |
| Oct 2023 | 125 |
| Nov 2023 | 125 |
| Dec 2023 | 125 |
| Jan 2024 | 125 |
| Feb 2024 | 125 |
| Mar 2024 | 157 |
| Apr 2024 | 157 |
| May 2024 | 157 |
| Jun 2024 | 157 |
| Jul 2024 | 157 |
iTeos Therapeutics other data
88.96%
-8.83%
of ITOS is owned by hedge funds
126
-24
33.47M
-3.81M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 5714285 | 0 |
| Nov 2024 | 5000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GALL MATTHEW officer: Chief Fi.. | Common Stock | 5,000 | $7.73 | $38,635 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. other: Former 10% Owner | Pre- Funded Warrants (Right to Buy) | 5,714,285 | $0 | $5,714 | ||
Purchase | GALL MATTHEW officer: Chief Fi.. | Common Stock | 5,000 | $8.37 | $41,850 | ||
Sale | BOXER CAPITAL, LLC | Common Stock | 34,846 | $14.19 | $494,465 | ||
Sale | BOXER CAPITAL, LLC | Common Stock | 95,516 | $15.63 | $1,492,915 | ||
Sale | BOXER CAPITAL, LLC | Common Stock | 219,638 | $16.87 | $3,705,293 | ||
Option | CALL MATTHEW officer: Chief Operating Officer | Common Stock | 40,226 | $2.95 | $118,667 | ||
Option | CALL MATTHEW officer: Chief Operating Officer | Stock Option (right to buy) | 40,226 | $2.95 | $118,667 | ||
Option | HALLAL DAVID director | Stock Option (Right to Buy) | 10,577 | $4.23 | $44,741 | ||
Option | HALLAL DAVID director | Stock Option (Right to Buy) | 11,899 | $2.95 | $35,102 |
| Quarter | Transcript |
|---|---|
| Q3 2021 11 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 13 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 14 May 2021 | Q1 2021 Earnings Call Transcript |
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail
iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall
iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through
iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of iTeos Therapeutics stock today?
One share of iTeos Therapeutics stock can currently be purchased for approximately $10.13.
-
When is iTeos Therapeutics's next earnings date?
Unfortunately, iTeos Therapeutics's (ITOS) next earnings date is currently unknown.
-
Does iTeos Therapeutics pay dividends?
No, iTeos Therapeutics does not pay dividends.
-
How much money does iTeos Therapeutics make?
iTeos Therapeutics has a market capitalization of 264.87M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 95.29% to 12.6M US dollars.
-
What is iTeos Therapeutics's stock symbol?
iTeos Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ITOS".
-
What is iTeos Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of iTeos Therapeutics?
Shares of iTeos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are iTeos Therapeutics's key executives?
iTeos Therapeutics's management team includes the following people:
- Dr. Michel Detheux Ph.D. Pres, Chief Executive Officer & Director(age: 59, pay: $833,750)
- Dr. Joanne Jenkins Lager M.D. Chief Medical Officer(age: 54, pay: $705,560)
- Mr. Matthew Gall Chief Financial Officer(age: 48, pay: $628,450)
-
How many employees does iTeos Therapeutics have?
As Jul 2024, iTeos Therapeutics employs 157 workers.
-
When iTeos Therapeutics went public?
iTeos Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.
-
What is iTeos Therapeutics's official website?
The official website for iTeos Therapeutics is iteostherapeutics.com.
-
Where are iTeos Therapeutics's headquarters?
iTeos Therapeutics is headquartered at 321 Arsenal Street, Cambridge, MA.
-
How can i contact iTeos Therapeutics?
iTeos Therapeutics's mailing address is 321 Arsenal Street, Cambridge, MA and company can be reached via phone at +33 92170161.
iTeos Therapeutics company profile:
iTeos Therapeutics, Inc.
iteostherapeutics.comExchange:
NASDAQ
Full time employees:
157
Industry:
Biotechnology
Sector:
Healthcare
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
321 Arsenal Street
Cambridge, MA 02472-5710
Cambridge, MA 02472-5710
CIK: 0001808865
ISIN: US46565G1040
CUSIP: 46565G104
